Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03645681 · ClinicalTrials.gov registry record · NA
Evaluating the Safety and Effectiveness of the InnAVasc Graft for Dialysis Access in Patients With Kidney Failure
A NA study, sponsored by W.L.Gore & Associates.
- Terminated
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT03645681 is a NA study that was terminated before completion, run by W.L.Gore & Associates. The registered enrollment target is 26 participants.
The verdict
NCT03645681, a NA study, was terminated before completion, sponsored by W.L.Gore & Associates.
- TERMINATED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
The CSP-1001 study will evaluate the safety and effectiveness of the InnAVasc arteriovenous graft (AVG) when implanted in and used for hemodialysis in participants suffering from end stage renal failure (ESRD). The InnAVasc AVG is implanted and used similar to other standard of care dialysis grafts currently on the market. However, the InnAVasc AVG has been uniquely designed to potentially allow for immediate needle access (same day as implant surgery as opposed to 2-4 weeks of waiting), to potentially reduce excessive bleeding from the graft after dialysis, and it may provide protection from improper or missed needle cannulation attempts.
Interventions
- DEVICE InnAVasc arteriovenous graft surgical implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-01-02 |
| Est. Completion | 2024-01-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03645681
The ClinicalTrials.gov registry entry for NCT03645681 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which InnAVasc arteriovenous graft surgical implant is the first listed.
NCT03645681 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03645681 about?
NCT03645681 is a clinical study titled "Evaluating the Safety and Effectiveness of the InnAVasc Graft for Dialysis Access in Patients With Kidney Failure". The CSP-1001 study will evaluate the safety and effectiveness of the InnAVasc arteriovenous graft (AVG) when implanted in and used for hemodialysis in participants suffering from end stage renal failure (ESRD). The InnAVasc AVG is implanted and used similar to other standard of care dialysis grafts ...
What is the current status of trial NCT03645681?
This trial is currently terminated. It is a NA study. The enrollment target is 26 participants. The study started on 2019-01-02. Estimated completion is 2024-01-16.
What interventions are being tested in trial NCT03645681?
The interventions under investigation include: InnAVasc arteriovenous graft surgical implant (DEVICE).
Who is sponsoring clinical trial NCT03645681?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.